NCT04922658View on ClinicalTrials.gov

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

Surufatinib

Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.

DRUG

Surufatinib Plus Vinorelbine

Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.

Trial Locations (1)

510095

RECRUITING

Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER